Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PhotonAB: Atezolizumab and Bevacizumab with Photon Radiotherapy in Unresectable HCC
NCT06339424Phase 2Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Chang Gung Memorial Hospital. Started Mar 2024; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06339424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06339424.